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All-trans retinoic acid (RA) has been implicated in
mediation of cardiac growth inhibition in neonatal cardiomyocytes. However, the associated signaling mechanisms remain unclear. Utilizing neonatal cardiomyocytes, we demonstrated that RA suppressed the
hypertrophic features induced by cyclic stretch or angiotensin II (Ang II). Cyclic stretch- or Ang II-induced
activation of extracellular signal-regulated kinase 1/2
(ERK1/2), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (MAP kinase) was doseand time-dependently inhibited by RA. Significant inhibition was observed by 5 M RA, from 8 to 24 h of pretreatment. This inhibitory effect was not mediated at
the level of mitogen-activated protein kinase kinases
(MKKs), because RA had no effect on stretch- or Ang
II-induced phosphorylation of MEK1/2, MKK4, and
MKK3/6. However, the phosphatase inhibitor vanadate
reversed the inhibitory effect of RA on MAP kinases and
protein synthesis. RA up-regulated the expression level
of MAP kinase phosphatase-1 (MKP-1) and MKP-2, and
the time course was correlated with the inhibitory effect
of RA on activation of MAP kinases. Overexpression of
wild-type MKP-1 inhibited the phosphorylation of JNK
and p38 in cardiomyocytes. These data indicated that
MKPs were involved in the inhibitory effect of RA on
MAP kinases. Using specific RAR and RXR antagonists,
we demonstrated that both RARs and RXRs were involved in regulating stretch- or Ang II-induced activation of MAP kinases. Our findings provide the first evidence that the anti-hypertrophic effect of RA is
mediated by up-regulation of MKPs and inhibition of
MAP kinase signaling pathways.

Retinoid is a generic term for synthetic and natural vitamin
A-related compounds, of which all-trans retinoic acid (RA)1 is a
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biologically active prototype. Retinoids participate in a wide
range of biological processes, including vision, neoplasia, embryonic development, normal reproductive function, regulation
of epithelial and hematopoietic cellular differentiation, and
cardiovascular development (2, 3). Retinoids function by binding to nuclear receptor proteins. Two families of retinoid receptors exist as follows: the retinoic acid receptor (RAR) family
(RAR␣, -␤, and -␥), bind both RA and 9-cis RA, and the retinoid
X receptor (RXR) family (RXR␣, -␤, and -␥), preferentially bind
9-cis RA (4, 5). These ligand-activated retinoid receptors act as
transcription factors, which bind to RA response elements in
the promoters/enhancers of numerous target genes, leading to
transcriptional stimulation or repression. Deficiency of vitamin
A has been linked to a variety of defects in cardiovascular
development, such as tetralogy of Fallot and supracristal ventricular septal defect (3). Embryonic deletions of individual
retinoid receptors induce a number of developmental abnormalities in the cardiovascular system (6, 7), and a predilection
for many of the same malformations seen with vitamin A
deficiency (8). On the other hand, overexpression of a constitutively active RAR in developing atria and/or in postnatal ventricles is relatively benign, while ventricular expression during
gestation can lead to dilated cardiomyopathy and significant
cardiac dysfunction (9, 10). It has been demonstrated that
RA-mediated signaling suppresses myocardial cell hypertrophy
in response to angiotensin II (Ang II), endothelin-1 (ET-1), and
the ␣-adrenergic receptor agonist phenylephrine (PE) (11–13).
These studies demonstrate that retinoid-dependent pathways
are involved in promoting the ventricular phenotype in embryonic heart, and indicate that retinoids may have an important
role in maintaining the normal ventricular phenotype in the
postnatal state. Although the anti-hypertrophic effect of RA in
neonatal cardiomyocytes has been demonstrated, the signaling
mechanisms of RA action are not well understood.
Cardiac hypertrophy is associated with the activation of numerous signal transduction factors, including G protein-coupled receptors, receptor-tyrosine kinases, protein kinase C, and
members of the mitogen-activated protein kinase (MAP kinase)
signaling cascade (14 –18). MAP kinases are serine/threonine
kinases that target substrates in a multilayered signaling network composed of the MAP kinases, the MAP kinase kinases
(MKKs), and the MEK kinases (MEKKs). MAP kinases can be
divided into three major subfamilies: extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), and
p38 MAP kinase. A large number of in vitro and in vivo studies
have identified important roles for the three branches of the
MAP kinase signaling pathway in cardiomyocyte hypertrophy
(19 –24). It has been shown that MAP kinase pathways are
activated and involved in various hypertrophic stimuli (growth
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factors, cytokines, and mechanical stretch) induced cardiac
hypertrophy, in vitro and in vivo (25–30). In response to MAP
kinase activation, a family of dual-specificity phosphatases,
MAP kinase phosphatases (MKPs), become transcriptionally
induced, leading to the specific dephosphorylation and inactivation of MAP kinases (31). MKP-1 is an important member of
the dual-specificity phosphatase family that is expressed in the
heart, where it regulates inactivation of p38, JNK1/2, and
ERK1/2 (32–34). Studies have shown that MKP-1 limits the
cardiac hypertrophic response in vitro and in vivo, via dephosphorylation and inactivation of MAP kinases (34 –36). Previous
studies have indicated a role of RA in regulating MAP kinase
pathways. RA inhibits serum-induced phosphorylation of JNK,
which is associated with a post-translational increase in the
level of MKP-1 protein in tumor cells (37). Up-regulation of
MKP-1 and inhibition of JNK phosphorylation is involved in
the antiapoptotic effect of RA on H2O2-exposed mesangial cells
(38). Although these observations clearly suggest a potential
link between retinoids and MAP kinase signaling, the mechanisms involved, particularly in hypertrophic cardiomyocytes,
have not been elucidated.
In the present study, we determined the effects of RA on
cyclic stretch- or Ang II-induced cardiac hypertrophy, and the
associated signaling mechanisms. Our results show that RA
had inhibitory effects on the activation of MAP kinases induced
by cyclic stretch or Ang II, and that the up-regulation of MKPs
by RA was involved. These results identify a mechanism
whereby RA regulates expression of MKPs and inhibition of
MAP kinases, which play an important role in the anti-hypertrophic effects of RA.
EXPERIMENTAL PROCEDURES

Materials—Cell culture reagents (Dulbecco’s modified Eagle’s medium/F12 Medium, horse serum, fetal bovine serum, and antibiotics) were
from Invitrogen (Baltimore, MD). Polyclonal antibodies against
ERK1/2, JNK1, p38, MKP-1, MKP-2, MKP-3, actin, RAR␣, RAR␤,
RAR␥, RXR␣, RXR␤, and RXR␥ were from Santa Cruz Biotechnology
(San Diego, CA). Phospho-MEK1, -MKK3, -MKK4, -ERK1/2, -JNK, and
-p38 antibodies were from Cell Signaling Technology (Beverly, MA).
PD98059, SB202190, and JNK inhibitor II (SP600125) were from Calbiochem (San Diego, CA). [␥-32P]ATP and [3H]leucine were from
PerkinElmer Life Science (Boston, MA). AGN193109 was a gift from
Allergan (Irvine, CA). HX531, a gift from Dr. Kagechika (The University of Tokyo, Japan) (39).
Cell Cultures—Monolayer cultures of neonatal cardiomyocytes were
prepared from the ventricles of 1–3-day-old Sprague-Dawley rat pups,
as previously described (40) and were cultured in 5% horse serum, 10%
fetal bovine serum, antibiotics, and 0.1 mM bromodeoxyuridine (prevent
proliferation of nonmyocytes) for 48 h at a density of 1.5 ⫻ 105 cells/cm2
in 100-mm culture dishes (for immunostaining in response to Ang II, in
2-well chamber slide) or in laminin-coated six-well BioFlex culture
plates (Flex Cell International Corporation). Cells were serum-starved
for 24 h prior to intervention. For the cyclic stretch model, serumstarved cells were subjected to cyclic stretch using the Flexcell 3000
Strain Unit. The vacuum produced a 15% elongation on the flexible
bottom membranes at a frequency of 60 cycles/min. Culture plates not
subjected to cyclic stretch were used as controls.
Adenovirus Generation—The replication-defective adenovirus-encoding wild-type MKP-1 (AdMKP-1, a gift from Dr. Molkentin, Children’s
Hospital Medical Center, Cincinnati, OH) was plaque purified, and
amplified using HEK293 cells. The multiplicity of viral infection (MOI)
for each virus was determined by dilution assay in HEK293 cells.
Cardiomyocytes were infected with adenovirus at a MOI of 25–50
plaque-forming units for 8 h at 37 °C. Subsequently, the cells were
cultured in serum-free Dulbecco’s modified Eagle’s medium/F12 media
for an additional 24 h before treatment or analysis.
Leucine Incorporation—Serum-starved cardiomyocytes were subjected to cyclic stretch or exposed to Ang II for 24 h. [3H]Leucine
(1Ci/ml) was added 4 h before harvest. The total radioactivity of
incorporated [3H]leucine into proteins was measured by liquid scintillation counting, as described previously (41).
Quantification of Total Cell Protein Content—The total protein content per cell number was determined as previously described (13).

Briefly, the same amount of cardiomyocytes were cultured in laminincoated 6-well BioFlex culture plates. After 24 h of serum starvation,
cardiomyocytes were pretreated, with or without RA (5 M) for 24 h, and
subjected to cyclic stretch (24 h) or exposed to Ang II (1 M, 36 h). Cells
were washed three times with 1⫻ phosphate-buffered saline, and dissolved in 2% SDS. Protein concentrations were measured using a DC
protein assay (Bio-Rad).
Immunocytochemistry—After 24 h of cyclic stretch or Ang II stimulation, cardiomyocytes were fixed in 3.7% paraformaldehyde, and permeabilized with 0.3% Triton X-100. Cells were incubated with Texas
Red-X phalloidin (1:40). Immunostained cardiomyocytes were viewed
by fluorescence microscopy. Quantitation of cell surface area was performed on actin-stained cardiomyocytes.
Western Blot Analysis—Cardiomyocytes were lysed in lysis buffer as
previously described (40, 42). Equal amounts of extracted proteins (50
g) were separated on 10% SDS-PAGE, transferred to nitrocellulose
membrane, and the Western blots probed with anti-MKP-1, MKP-2, or
MKP-3 antibody or antibodies specific for the phosphorylated forms of
MEK1, MKK3, MKK4, ERK1/2, JNK, or p38. Membranes were reprobed with unphosphorylated forms of corresponding antibodies to confirm equal loading. Primary antibody binding was detected with horseradish peroxidase-conjugated goat anti-mouse or goat anti-rabbit
secondary antibody and visualized by chemiluminescence (PerkinElmer
Life Sciences).
Extraction of Nuclear Proteins and the Expression of RARs and
RXRs—Cardiomyocytes were rinsed with phosphate-buffered saline at
4 °C and scraped into the same buffer. Nuclear extracts were prepared
according to standard methods described previously (40, 43). Equal
amounts of extracted nuclear proteins (20 g) were separated on 10%
SDS-PAGE and transferred to nitrocellulose membrane. The expression level of RARs and RXRs was determined using anti-RAR␣, -␤, -␥,
RXR␣, -␤, and -␥ antibodies. Another set of samples was probed with
anti-histone antibody, as a control for equal protein loading.
Gel Mobility Shift Assay—To determine the transcriptional activation of RAR and RXR, gel shift assay was performed as described
previously (40). Five micrograms of nuclear extract were incubated with
1 g of poly(dI-dC)-poly(dI-dC) and radiolabeled probes (⬃10,000 cpm)
in 20 l of 10 mM HEPES (pH 7.9), 50 mM NaCl, 1 mM EDTA, and 10%
glycerol for 30 min at 25 °C. The probes were purchased from Santa
Cruz Biotechnology, and their sequences have been described (RAR:
5⬘-AGGGTAGGGTTCACCGAAAGTTCACTC-3⬘, RAR mutant: 5⬘AGGG TAGGGAACACCGAAAGTTCACTC-3⬘; RXR: 5⬘-AGCTTCAGGTCAGAGGTCAGAGAG CT-3⬘, and RXR mutant: AGCTTCAGCACAGAGCACAGAGAGCT-3⬘). The oligonucleotides were labeled with
[␥-32P]ATP using T4 polynucleotide kinase. Binding reactions were
resolved on a 4% native polyacrylamide gel containing 1⫻ TAE buffer
(40 mM Tris, pH 7.5, 40 mM sodium acetate, and 1 mM EDTA) for 3 h at
150 V in 4 °C. The gel was dried, and exposed to x-ray film.
Statistical Analysis—Data were expressed as the mean ⫾ S.E. Statistical differences were determined using a Student’s t test (p ⬍ 0.05).
RESULTS

RA Inhibits Cyclic Stretch- and Ang II-induced Cardiomyocyte Hypertrophy—To determine the effects of RA on cardiac
hypertrophy, cardiomyocytes were pretreated with or without
RA for 24 h, and subjected to cyclic stretch or exposed to Ang II
for an additional 24 h. Cell morphological changes were observed. Cyclic stretch and Ang II stimulation induced a marked
increase in cell size, which was significantly inhibited by RA
(Fig. 1, A and B). RA treatment also reduced the accumulation
of sarcomeric fibers and the myofibrillar reorganization in response to Ang II and cyclic stretch (Fig. 1A). RA alone had no
effect on myocardial cell phenotype, indicating that the effect of
RA was not secondary to a toxic cellular effect. In addition to
the specific effects on cell morphology, cardiac hypertrophy is
accompanied by an increase in protein synthesis. In an effort to
determine the effects of RA on protein synthesis, we performed
[3H]leucine incorporation, which is an index of protein synthesis. As shown in Fig. 1C, cyclic stretch and Ang II stimulation
resulted in a significant increase in [3H]leucine incorporation,
which was inhibited by RA. RA alone had little inhibitory effect
on the basal level, but no significant difference compared with
control. We also determined the effect of RA on total protein
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FIG. 1. RA inhibits cyclic stretch- and Ang II-induced cardiac hypertrophy. A, cardiomyocytes were pretreated with or without RA (5 M)
for 24 h, and subjected to cyclic stretch (ST) or exposed to Ang II for another 24 h. Control cells were pretreated with Me2SO. Immunofluorescence
was performed with Texas Red pholloidin antibody. B, pholloidin-stained cells were imaged and cell surface areas calculated with the Image J
Program (n ⫽ 100 cells each). *, p ⬍ 0.001 versus control; #, p ⬍ 0.001 versus stretch or Ang II without RA. C, cardiomyocytes were subjected to
stretch or exposed to Ang II for 24 h, with or without RA pretreatment for 24 h. [3H]Leucine (1 Ci/ml) was added 4 h before cell harvest. The total
radioactivity of incorporated [3H]leucine into proteins, was measured by liquid scintillation counting. Each bar represents the mean ⫾ S.E. of six
separate experiments. *, p ⬍ 0.05 versus control and #, p ⬍ 0.05 versus stretch or Ang II. D, effects of RA on total protein content. Cardiomyocytes
were pretreated with or without RA (5 M) for 24 h, and subjected to stretch (24 h) or exposed to Ang II (1 M, 36 h). Total protein content was
determined using the DC protein assay. Values are means ⫾ S.E. (n ⫽ 12 in each group). *, p ⬍ 0.05 versus control; #, p ⬍ 0.001 versus stretch;
##, p ⬍ 0.05 versus Ang II.

content. As shown in Fig. 1D, 24 h of stretching or 36 h of Ang
II stimulation induced approximately a 40 and 35% increase in
total protein content, respectively (compared with control),
which was inhibited by RA pretreatment. Total protein content
increased about 8% in the myocytes incubated with 5 M RA
alone, but there was no significant difference compared with
control. These results suggest that RA suppresses cyclic
stretch- or Ang II-induced cardiac hypertrophy.

RA Inhibits Cyclic Stretch-induced Activation of MAP Kinases—Accumulating data have shown that MAP kinases are
important mediators in cardiac hypertrophy. We determined
the involvement of MAP kinases in the anti-hypertrophic effect
of RA. Cardiomyocytes were pretreated with or without RA for
different times and subjected to cyclic stretch for 8 min. ERK,
JNK, and p38 MAP kinase activity was determined by Western
blot analysis, using specific antibodies against phospho-
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ERK1/2, -JNK1/2, and p38. RA time-dependently inhibited
stretch-induced phosphorylation of ERK, JNK, and p38 (Fig.
2A). Although the inhibitory effect was observed beginning at
2 h of RA pretreatment (p ⬎ 0.05, compared with stretch,
bottom panel), the most significant inhibition was observed
from 8 to 24 h (p ⬍ 0.05, compared with stretch). Stretchinduced phosphorylation of MAP kinases was also dose-dependently inhibited by 24 h of RA pretreatment (Fig. 2B). The
phosphorylation of MAP kinases was significantly inhibited by
5–10 M of RA (p ⬍ 0.05, compared with stretch, bottom panel),
whereas a low dose of RA (0.1–1 M) had no effect. The involvement of MAP kinases in stretch-induced cardiac hypertrophy
was further determined using specific inhibitors for ERK
(PD98059, PD), JNK (SP600125, SP), and p38 (SB202190, SB).
Cardiomyocytes were subjected to stretch for 24 h, in the presence or absence of inhibitors. [3H]leucine incorporation was
performed. As shown in Fig. 2C, the stretch-induced increase in
leucine incorporation was significantly inhibited by 70, 50, and
40%, respectively, in PD98059-, SP600125-, or SB202190treated cardiomyocytes, indicating that all three MAP kinases
were involved in the stretch-mediated hypertrophic process.
Taken together, our results suggested that MAP kinase pathways were involved in the inhibitory effects of RA on cyclic
stretch-induced cardiac hypertrophy.
RA Inhibits Ang II-induced Activation of MAP Kinases—
Studies have shown that RA suppressed Ang II-induced cardiac
hypertrophy (13). Thus, we determined whether MAP kinases
were also involved in RA action. As shown in Fig. 3A, Ang II
induced rapid phosphorylation of ERK1/2 and p38 at 2 min,
which was sustained to 60 min, and returned to a basal level at
120 min. On the other hand, the phosphorylation of JNK1/2 in
response to Ang II, was observed from 2 min, with peak phosphorylation observed at 40 – 60 min. The involvement of MAP
kinases in Ang II-induced protein synthesis was determined.
Cardiomyocytes were exposed to Ang II for 24 h, in the presence or absence of PD98059, SP600125, or SB202190, and [3H]
leucine incorporation was determined. The Ang II-induced increase in leucine incorporation was inhibited by PD98059,
SP600125, or SB202190 (inhibited by 60, 45, and 30%, respectively, compared with Ang II). We further determined the effect
of RA on Ang II-induced activation of MAP kinases. Western
blot analysis demonstrated that RA pretreatment inhibited
Ang II-induced activation of MAP kinases, in a time- and dosedependent manner. Significant inhibition by RA was observed
from 8 to 24 h, at a dose of 5–10 M (p ⬍ 0.05, compared with
Ang II, Fig. 3, C and D). RA pretreatment for 2– 4 h at 0.1–1 M
did not significantly inhibit Ang II-induced activation of MAP
kinases (p ⬎ 0.05, Fig. 3, C and D, bottom panel).
RA Has No Effect on the Activation of MKKs—All MAP
kinase pathways share a three-component cascade mode of
activation, in which MKKK phosphorylates a dual-specificity
kinase MKK, which specifically recognizes and activates different MAP kinases (44). Therefore, we determined whether the
inhibitory effect of RA on the activation of MAP kinases, was
caused by the inhibition of MKK activation. The phosphorylation of MKKs was examined by immunoblotting with specific
antibodies against phospho-MEK1, -MKK3/6, and -MKK4. Cardiomyocytes were pretreated with or without 5 M RA, up to
24 h, and subjected to cyclic stretch for 1 and 3 min (Fig. 4A),
or exposed to Ang II for 3 min (Fig. 4B). Cyclic stretch or Ang
II stimulation induced rapid phosphorylation of MEK1,
MKK3/6, and MKK4. Pretreatment of cardiomyocytes with RA
did not affect the phosphorylation of MEK1, MKK4, and
MKK3/6. These results indicated that the inhibitory effect of
RA on the activation of MAP kinases was not mediated at the
level of MKKs.

Vanadate Reverses the Inhibitory Effect of RA on the Activation of MAP Kinases and Leucine Incorporation—Once activated, MAP kinases are rapidly inactivated by the family of
dual-specificity protein phosphatases. To determine the role of
phosphatases in regulating RA action on MAP kinases, we
examined whether the inhibition of MAP kinases by RA could
be prevented by the phosphatase inhibitor, vanadate. Cardiomyocytes were pretreated with RA for 24 h in the absence or
presence of vanadate, and subjected to cyclic stretch for 8 min,
or exposed to Ang II for 3 min (for ERK and p38) or 40 min (for
JNK). Western blot analysis demonstrated that the inhibitory
effect of RA on stretch- or Ang II-induced activation of MAP
kinases was significantly reversed by vanadate (Fig. 5, A and
B). Treatment with vanadate alone minimally increased the
basal level of MAP kinases, but there was no significant difference compared with control. Under similar conditions, the role
of phosphatases in the anti-hypertrophic effect of RA was determined. After 24 h of stimulation with cyclic stretch or Ang
II, [3H]leucine incorporation was performed. RA inhibited the
increased leucine incorporation in response to cyclic stretch or
Ang II, and vanadate treatment increased leucine incorporation in the presence of RA, indicating the inhibitory effect of RA
on leucine incorporation was reversed by vanadate (Fig. 5C).
Vanadate alone had no effect. These data suggested that protein phosphatases were involved in regulating the inhibitory
effects of RA on MAP kinases and protein synthesis.
Induction of MKPs by RA in Cardiomyocytes—MKPs are a
family of inducible dual-specificity phosphatases (45), which
dephosphorylate and inactivate MAP kinases (46, 47). To determine whether the suppression of MAP kinases by RA is
mediated by MKPs, we tested the protein expression level of
MKPs in cardiomyocytes. Cells were treated with RA up to
48 h, and Western blot analysis was performed. RA increased
the protein level of MKP-1 and MKP-2 in a dose- and time-dependent manner (Fig. 6, A–C). The expression level of MKP-1
and MKP-2 was up-regulated by RA from 2 h of treatment, and
peaked at 24 – 48 h. The expression level of MKP-3 was not
significantly affected by RA. RA-induced up-regulation of
MKP-1 and MKP-2 was consistent with the inhibitory pattern
of RA on activation of MAP kinases, suggesting that up-regulated MKP-1 and MKP-2, may contribute to the inhibitory
effect of RA on the activation of MAP kinases.
RA Increases MKPs Expression at the Transcriptional and
Translational Levels—Previous studies have shown that the
induction of MKPs by RA is variable (37, 38), suggesting that
RA may differentially regulate the expression of MKPs depending on the cell type. To determine the regulatory mechanisms of
MKP expression by RA in neonatal cardiomyocytes, a RNA
synthesis inhibitor actinomycin D (ActD), and a protein synthesis inhibitor cycloheximide (CHX) was used. Cardiomyocytes were treated with RA for 3, 6, and 24 h, in the presence or
absence of ActD or CHX. Western blot analysis showed that
RA-induced expression of MKP-1 and MKP-2 was blocked by
ActD or CHX (Fig. 7, A and B). These data suggested that RA
regulated the expression of MKPs at both transcriptional and
translational levels in neonatal cardiomyocytes.
MKP-1 Overexpression Inhibits the Activation of MAP Kinases and Leucine Incorporation—To determine the role of
MKPs in regulating the activation of MAP kinases in cardiomyocytes, an MKP-1-expressing adenovirus (AdMKP-1) was
used. Cardiomyocytes were infected with different doses of
AdMKP-1, which resulted in a dose-dependent overexpression
of MKP-1 (Fig. 8A). The role of MKP-1 in cyclic stretch- or Ang
II-mediated cardiac hypertrophy was also determined. After
infection with AdMKP-1, cells were subjected to stretch or
exposed to Ang II for 24 h. [3H]leucine incorporation assay
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FIG. 2. RA inhibits cyclic stretch-induced phosphorylation of MAP kinases in a time- and dose-dependent manner. A, cardiomyocytes were pretreated with or without RA (5 M) for different times, then subjected to cyclic stretch for 8 min. Cell extracts (50 g) were subjected
to 10% SDS-PAGE and immunoblotted with an antibody specific for phospho-ERK1/2, -JNK, or -p38 MAP kinase. Membranes were stripped and
reprobed for total ERK1/2, JNK1, or p38, as a control for equal protein loading (upper panel). B, cardiomyocytes were pretreated with different
doses of RA for 24 h as indicated, and subjected to stretch for 8 min. The phosphorylation of ERK1/2, JNK1/2, and p38 was determined (upper
panel). Phosphorylated levels of ERK1/2, JNK1/2, or p38 were quantified by densitometric scanning, and normalized to the level of total ERK, JNK,
or p38 (A and B, bottom panel). Data represent average fold increase of controls from three independent experiments (mean ⫾ S.E.). *, p ⬍ 0.05
versus control; #, p ⬍ 0.05 versus stretch. C, role of MAP kinases in the stretch-induced increase in protein synthesis. Cardiomyocytes were
subjected to stretch for 24 h, in the presence or absence of PD98059 (PD, 50 M), SB202190 (SB, 10 M), or SP600125 (SP, 20 M). The incorporated
[3H]leucine was measured by liquid scintillation counting. Each bar represents the mean ⫾ S.E. of six separate experiments. *, p ⬍ 0.05 versus
control; #, p ⬍ 0.05 versus stretch.
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FIG. 3. RA inhibits Ang II-induced phosphorylation of MAP kinases in a time- and dose-dependent manner. A, Ang II induces
phosphorylation of MAP kinases. Cardiomyocytes were exposed to Ang II (0.1 M) for the times indicated. The phosphorylation of ERK1/2, JNK1/2, and
p38 was determined, as described in Fig. 2A. B, cardiomyocytes were exposed to Ang II for 24 h, in the presence or absence of PD98059 (PD, 50 M),
SB202190 (SB, 10 M), or SP600125 (SP, 20 M), and [3H]leucine incorporation was measured. Each bar represents the mean ⫾ S.E. of six separate
experiments. *, p ⬍ 0.05 versus control; #, p ⬍ 0.05 versus Ang II; ##, p ⬍ 0.001 versus Ang II. C, cardiomyocytes were pretreated with RA (5 M) for
the times indicated, then exposed to Ang II for 3 min (for ERK1/2 and p38) or 40 min (for JNK), and the phosphorylation of ERK1/2, JNK1/2, and p38
determined (upper panel). D, cardiomyocytes were pretreated with different doses of RA for 24 h, exposed to Ang II for 3 min (ERK and p38), or 40 min
(JNK), and the phosphorylation of ERK1/2, JNK1/2, and p38 determined by Western blotting (upper panel). Phosphorylated levels of ERK1/2, JNK1/2,
or p38 were quantified by densitometric scanning, and normalized to the level of total ERK1, JNK, or p38 (C and D, bottom panel). Data represent the
average fold increase of controls from three independent experiments (mean ⫾ S.E.). *, p ⬍ 0.05 versus control; #, p ⬍ 0.05 versus Ang II.
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FIG. 4. Effect of RA on stretch- or Ang II-induced phosphorylation of MKKs. A, cardiomyocytes were pretreated with or without RA (5
M) for 24h, and subjected to cyclic stretch for 1 and 3 min. An equal amount of proteins (50 g) was subjected to 10% SDS-PAGE, and the
phosphorylation of MKKs detected by immunoblotting with antibody specific to phospho-MEK1, -MKK4, or MKK3/6. Membranes were reprobed
for total MEK1, MKK4, and MKK3, as a control for equal protein loading. B, cardiomyocytes were pretreated with RA (5 M) for the times indicated,
then exposed to Ang II (0.1 M) for 3 min. The phosphorylation of MKKs was determined, as described above.

demonstrated that the increased leucine incorporation induced
by cyclic stretch or Ang II was significantly inhibited by overexpression of MKP-1. AdLacZ (control virus) or AdMKP-1 alone
had no effect on the basal level of [3H]leucine incorporation
(Fig. 8B). Additionally, the effect of AdMKP-1 on activation of
MAP kinases was determined. After 24 h of infection, cardiomyocytes were subjected to cyclic stretch, or exposed to Ang II,
and the phosphorylation of ERK1/2, JNK1/2, and p38 was
examined. Cyclic stretch or Ang II-induced phosphorylation of
JNK1/2 and p38 was significantly inhibited by overexpression
of MKP-1 (p ⬍ 0.05, compared with stretch or Ang II stimulation group, Fig. 8, C and D), and that of ERK1/2 was partially
inhibited (p ⬎ 0.05, compared with stretch or Ang II). AdLacz
or AdMKP-1 alone had no effect on the phosphorylation of MAP
kinases, whereas total protein levels of each MAP kinase
were unchanged.
RA Induces Expression and Activation of RARs and RXRs in
Cardiomyocytes—It has been demonstrated that both RAR and
RXR, especially RAR/RXR heterodimers, mediate suppression
of PE and ET-1-induced cardiac hypertrophy (11). To further
establish the role of RAR and RXR in RA-induced anti-hypertrophic effects, we determined whether RA influences the expression and activation of RARs and RXRs in cardiomyocytes.
Cells were exposed to RA up to 24 h, and nuclear extracts
prepared following standard methods (40, 48). The protein level
of RARs and RXRs was determined by Western blot, using
specific anti-RAR␣, -RAR␤, -RAR␥, -RXR␣, -RXR␤, and -RXR␥
antibodies. As shown in Fig. 9A, all of the RARs and RXRs were
expressed in neonatal cardiomyocytes. The expression of
RAR␣, RXR␣, and RXR␥ was found to be the most abundant,
whereas RAR␥ was expressed weakly in neonatal cardiomyocytes. RA increased the expression level of RARs and RXRs
after 30 min of treatment, which was sustained to 24 h. DNA
binding activity of RAR and RXR was determined by electrophoretic mobility shift assays (EMSA), using oligonucleotides
corresponding to the RAR or RXR binding site, as described
previously (49). The DNA-protein complex with RAR was observed after 30 min of RA treatment, and peaked at 1–2 h. The
DNA-protein complex with RXR was observed after 30 min,
peaked at 2– 4 h, and decreased thereafter (Fig. 9B). These

results indicated that both RAR and RXR were induced and
activated by RA.
Role of RAR and RXR in Regulating the Phosphorylation of
MAP Kinases—To determine the role of RAR and RXR in the
regulation of the activation of MAP kinases, a specific RAR
antagonist (AGN193109) and RXR antagonist (HX531) were
used. Cells were pretreated with or without AGN193109 or HX
531 for 1 h, and then exposed to RA for 24 h, and subjected to
stretch for 8 min (Fig. 10A) or exposed to Ang II for 3 min (ERK
and p38) or 40 min (JNK) (Fig. 10B). Cyclic stretch- or Ang
II-induced phosphorylation of ERK1/2, JNK1/2, and p38 was
inhibited by RA, as demonstrated (Figs. 2 and 3). Although
AGN193109 partially reversed the inhibitory effect of RA on
stretch- or Ang II-induced phosphorylation of ERK1/2, JNK1/2,
and p38, there was no significant difference compared with the
RA treatment group (p ⬎ 0.05, Fig. 10, A and B, bottom panel).
HX531 almost completely reversed the inhibitory effect of RA
on both stretch and Ang II-induced activation of MAP kinases
(p ⬍ 0.05, compared with RA treatment group). Based on these
observations, activation of RXR or the heterodimerization of
RAR and RXR may have an important role in the regulation of
the activation of MAP kinases induced by cyclic stretch or
Ang II.
DISCUSSION

RA suppresses ET-1, PE, and Ang II-induced hypertrophic
responses in neonatal cardiomyocytes (11–13). However, the
signaling mechanisms of RA action were not known. We provide the first evidence that RA inhibits the activation of MAP
kinases induced by cyclic stretch or Ang II, by regulating the
expression of MKP-1 and MKP-2 in cardiomyocytes. This represents a novel mechanism by which RA regulates cardiomyocyte growth inhibition.
In the present study, we demonstrated that cyclic stretch- or
Ang II-induced cardiac hypertrophic features, including increased total protein content, protein synthesis, cell size, and
myofibrillar reorganization were significantly inhibited by RA
pretreatment, suggesting that retinoid-mediated signaling
pathways have an important role in regulating cyclic stretchor Ang II-induced cardiomyocyte growth. Previous studies have
suggested that RA has a role in regulating the activation of
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FIG. 5. Vanadate reverses the inhibitory effect of RA on MAP kinases and protein synthesis. To determine whether RA-mediated
suppression of MAP kinases is regulated by protein phosphatases, cardiomyocytes were pretreated, with or without vanadate (Va, 10 M) for 1 h,
treated with or without RA (5 M) for 24 h, then subjected to cyclic stretch for 8 min (A, upper panel), or exposed to Ang II for 3 (ERK and p38)
or 40 min (JNK) (B, upper panel), the phosphorylation of ERK1/2, JNK1/2, and p38 was detected by Western blotting, as described in the legend
to Fig. 2A. Phosphorylated levels of ERK1/2, JNK1/2, or p38 were quantified by densitometric scanning, and normalized to the level of total ERK,
JNK, or p38 (A and B, bottom panel). Data represent average fold increase of controls from three independent experiments (mean ⫾ S.E.). *, p ⬍
0.05 versus control; #, p ⬍ 0.05 versus stretch or Ang II. ##, p ⬍ 0.05 versus RA plus stretch or Ang II. C, under similar conditions, cardiomyocytes
were stimulated by cyclic stretch or Ang II for 24 h, after pretreatment with vanadate and RA. [3H]Leucine incorporation was performed, as
described in the legend to Fig. 1C. Each bar represents the mean ⫾ S.E. of six separate experiments. *, p ⬍ 0.05 versus control; #, p ⬍ 0.05 versus
stretch or Ang II; ##, p ⬍ 0.05 versus RA plus stretch or Ang II.
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FIG. 6. RA induces expression of MKPs. A, cardiomyocytes were treated with RA (5 M) for the times indicated, and the expression level of
MKPs determined by Western blot using anti-MKP-1, -MKP-2, and -MKP-3 antibodies. Another set of samples was Western-blotted using
anti-actin antibody, to serve as a loading control. Densitometric analysis of data is shown in B. The intensity of each message was normalized to
the level of actin. C, cells were treated with different doses of RA for 24 h, and the expression of MKP-1 and MKP-2 was determined. The data are
representative of three separate experiments.

FIG. 7. Effect of actinomycin D and cycloheximide on RA-induced expression of MKPs. Cardiomyocytes were treated with RA (5
M) for 3, 6, and 24 h, in the presence or absence of actinomycin D
(ActD, 5 g/ml, A) or cycloheximide (CHX, 50 M, B), and subjected to
Western blot analysis. The expression level of MKP-1 and MKP-2 was
normalized to actin.

MAP kinase signaling pathways in other cell lines (37, 38).
Here we determined whether there was a link between RA and
MAP kinase signaling in hypertrophic cardiomyocytes. Our
results showed that RA time- and dose-dependently inhibited
cyclic stretch- and Ang II-induced activation of ERK1/2,
JNK1/2, and p38. Significant inhibition was observed following
5–10 M RA pretreatment. Although the activation of MAP
kinases was inhibited by 5 M RA from 2 h of pretreatment,

significant inhibition was observed from 8 –24 h of RA treatment, suggesting that retinoid receptor transcriptional activation was involved in regulating the late, sustained suppression
of MAP kinases by RA. All three MAP kinases have been
implicated as important transducers of the hypertrophic
growth response, both in cell culture-based studies and in the
intact heart (50 –52). Using specific inhibitors for MEK1/2,
JNK, or p38 MAP kinase, we demonstrated that all three MAP
kinases were differentially involved in regulating the cyclic
stretch- and Ang II-induced increase in protein synthesis. One
potential mechanism whereby MAP kinases promote hypertrophy is by regulating the activation of GATA4, a cardiac-expressed transcription factor, which has been demonstrated to
be involved in cardiac hypertrophy (53–55). GATA4 is directly
regulated by ERK1/2 and p38 MAP kinase signaling effectors,
resulting in augmented hypertrophic gene expression (56, 57).
It has recently been shown that RA inhibits the hypertrophic
gene expression through regulation of the transcriptional activity of GATA4 (58). In the present study, we provided additional evidence for understanding the signaling mechanism of
RA action in neonatal cardiomyocytes. RA inhibits the activation of MAP kinases, which may lead to inactivation of GATA4,
or other transcription factors such as AP-1, resulting in inhibition of the increase in cell size and protein synthesis induced
by cyclic stretch and Ang II.
The precise mechanism by which RA mediates suppression of
MAP kinases is not well defined. The activation of MAP kinases by stretch or Ang II is regulated by their upstream
kinases (MKKs) (50, 51, 59). We demonstrated that both cyclic
stretch and Ang II induced rapid phosphorylation of MEK1/2,
MKK3, and MKK6. It is possible that the inhibitory effects of
RA on MAP kinases may be regulated through inhibition of
MKKs. Surprisingly, RA had no effect on the cyclic stretch- or
Ang II-induced phosphorylation of MEK1/2, MKK4, and
MKK3/6, suggesting that the inhibitory effects of RA on MAP
kinases were mediated through MKK-independent pathways.
It has previously been shown that inactivation of MAP kinases is primarily achieved by a group of MKPs (60, 61). To
date, 10 MKP family members have been cloned, some of which
are encoded by immediate-early genes, such as MKP-1 and
MKP-3 (62– 65). MKPs differ by properties such as tissue-
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FIG. 8. Overexpression of MKP-1 inhibits the activation of MAP kinases and protein synthesis. A, cardiomyocytes were infected with
AdLacZ or AdMKP-1 adenovirus at different MOIs, as indicated, and after 24 h, cell lysates (50 g) were subjected to SDS-PAGE. The
overexpression of MKP-1 was detected using anti-MKP-1 antibody. B, cardiomyocytes were infected with 50 MOI of AdLacZ or AdMKP-1, and after
24 h, subjected to cyclic stretch or exposed to Ang II for an additional 24 h. [3H]Leucine incorporation was performed as described in Fig. 1C. Each
bar represents the mean ⫾ S.E. of six separate experiments. *, p ⬍ 0.05 versus control and #, p ⬍ 0.05 versus stretch or Ang II. After infection with
AdMKP-1, cardiomyocytes were subjected to cyclic stretch for 8 min (C) or exposed to Ang II for 3 min (ERK, p38) or 40 min (JNK) (D). The
phosphorylation of MAP kinases was determined using specific phospho-ERK1/2, -JNK, or -p38 antibodies. Membranes were reprobed for total
ERK1/2, JNK1, or p38, as a control for equal protein loading. Phosphorylated levels of ERK1/2, JNK1/2, or p38 were quantified by densitometric
scanning, and normalized to the level of total ERK1, JNK, or p38 (C and D, bottom panel). Data represent average fold increase of controls from
three independent experiments (mean ⫾ S.E.). *, p ⬍ 0.05 versus control; #, p ⬍ 0.05 versus stretch or Ang II.
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FIG. 9. RA induces expression and activation of RARs and RXRs. A, cardiomyocytes were stimulated by RA for the times indicated. Equal
amounts of extracted nuclear proteins (20 g) were separated on 10% SDS-PAGE, transferred to nitrocellulose membrane, and the expression of
RARs and RXRs detected using anti-RAR␣, -␤, -␥, and -RXR␣, -␤, and -␥ antibodies. Another set of nuclear proteins was Western blotted using
anti-histone antibody, to verify equal loading. B, gel mobility shift assay was performed using nuclear extracts from RA-treated cardiomyocytes.
Nuclear extracts (5 g) were incubated with the 32P-labeled RAR or RXR oligonucleotide for 20 min at 25 °C and resolved by native 4% TAE
polyacrylamide gel electrophoresis. A mutant-labeled RAR or RXR oligonucleotide was used as a negative control (last lane).

specific expression, differential regulation in response to various stimuli, distinct subcellular localization, and substrate
specificity (66). MKP-1 and MKP-2 are widely expressed in
various tissues, including heart, where they regulate inactivation of p38, JNK1/2, and ERK1/2 (32–34, 45– 47). Various stimuli, such as growth factors, stress, phorbol ester, and vasoactive
peptides, have been reported to induce MKP-1 and MKP-2
mRNA expression (45, 64, 67, 68). Studies have shown that
MKP-1 limits the cardiac hypertrophic response, in vitro and in
vivo, via dephosphorylation and inactivation of MAP kinases
(34 –36). RA induces expression of MKP-1 in non-small cell
lung cancer cells, a mouse embryonic P19 stem cell line, rat
fibroblast cell line NRK49F, and mesangial cells. The expression of MKP-1 is differentially regulated at transcriptional or
translational levels in different cell lines (37, 38, 69). Conversely, RA has no effect on the expression of MKP-1 in rat
aortic smooth muscle cells (70). These data indicate that the
regulation of MKPs by RA is a cell specific response. Our data
showed that the protein expression of MKP-1 and MKP-2 was
dose- and time-dependently up-regulated by RA. The up-regulation was observed from 4 h of treatment with RA, peaked at
24 h, and was sustained to 48 h. The up-regulation of MKP-1
and MKP-2 was blocked by either inhibition of RNA synthesis
or protein synthesis, suggesting that RA regulates the expression of MKPs at both the transcriptional and translational level
in cardiomyocytes. It has been reported that RA inhibits H2O2
and serum-induced phosphorylation of JNK, via up-regulation
of MKP-1 (37, 38). It is notable that RA suppresses the activation of MAP kinases through up-regulation of MKPs in neonatal cardiomyocytes. Several of our findings support this latter
possibility as follows: First, the inhibition of MAP kinases by
RA was attenuated by vanadate, a potent inhibitor of proteintyrosine phosphatases, including MKP-1 and MKP-2 (64, 71,
72), and the inhibitory effect of RA on increased protein synthesis was also reversed by vanadate. Second, overexpression

of MKP-1 in cardiomyocytes significantly inhibited cyclic
stretch- and Ang II-induced phosphorylation of JNK and p38,
and the increase in protein synthesis. The phosphorylation of
ERK1/2 was only partly inhibited by overexpression of MKP-1,
indicating that other MKPs may also have contributed to the
suppression of MAP kinases by RA. Third, RA treatment induced up-regulation of MKP-1 and MKP-2 in cardiomyocytes,
the time course of which is correlated with the inhibitory effect
of RA on the activation of MAP kinases. These findings suggested that up-regulation of MKP-1 and MKP-2 had an important role in the suppression of MAP kinase activities by RA.
The transcriptional regulatory effects mediated by RA are
influenced at multiple levels, such as specificity of the ligandreceptor interaction, and temporal and spatial variations in
receptor expression. Previous studies have shown that retinoid
receptors are required at early stages of cardiac development,
support cell proliferation, and control the shape of ventricular
myocytes (6, 7). Both RXRs and RARs may participate in the
mediation of these functions (6, 7, 73). In the post-development
period, the retinoid receptor is involved in preserving the normal differentiated phenotype of cardiomyocytes, by antagonizing the effect of various hypertrophic stimuli (11–13). However,
very little is known about the regulation of retinoid receptor
expression in response to RA in neonatal cardiomyocytes. In
the adult rat heart, RXR␥ is predominantly expressed, compared with RXR␣ and RXR␤. The positive regulation of RXR␤
and negative regulation of RXR␥ by thyroid hormone is observed in adult rat heart (74). RXR␥ though not detectable in
embryonic heart, is expressed in neonatal cardiomyocytes and
developmentally regulated during the postnatal period (75). All
of the retinoid receptors were expressed and induced by RA in
neonatal cardiomyocytes. RAR␣, RXR␣, and RXR␥ were the
most abundant receptors, whereas RAR␥ was weakly expressed. Both RAR and RXR were transcriptionally activated
by RA. It has been shown that RARs and RXRs have different
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FIG. 10. The role of RAR and RXR in mediating the activation of MAP kinases. To determine the role of RAR and RXR in regulation of
the activation of MAP kinases, a specific RAR antagonist AGN193109 (AGN, 1 M), and RXR antagonist HX531 (1 M) was used. Cells were
pretreated with or without AGN193109 or HX531 for 1 h, treated with or without RA (5 M) for 24 h, and subjected to stretch (A) or exposed to
Ang II (B). The phosphorylation of ERK1/2, JNK1/2, and p38 was determined, as described in Fig. 2. Phosphorylated levels of ERK1/2, JNK1/2,
or p38 were quantified by densitometric scanning, and normalized to the level of total ERK, JNK, or p38 (A and B, bottom panel). Data represent
average fold increase of controls from three independent experiments (mean ⫾ S.E.). *, p ⬍ 0.05 versus control; #, p ⬍ 0.05 versus stretch or Ang
II; ##, p ⬍ 0.05 versus RA plus stretch or Ang II.

roles in regulating the inhibitory effect of RA on activation of
JNK (38, 76). To determine the role of RAR and RXR in RAinduced suppression of the activation of MAP kinases in cardiomyocytes, specific receptor antagonists were used. Our data
showed that antagonizing RARs, had a minor effect on the
activation of MAP kinases. However, RXR antagonist significantly reversed the inhibited activation of MAP kinases induced by RA, indicating that RXR or the heterodimerization of

RAR and RXR, is involved in regulating the activation of MAP
kinases induced by cyclic stretch or Ang II. These data suggested that RA effects were mediated through both RAR- and
RXR-regulated signaling pathways, resulting in suppression of
the hypertrophic responses induced by cyclic stretch or Ang II.
Previous studies have shown that RA antagonizes the hypertrophic growth of cardiomyocytes. The results presented here
were focused on the signaling mechanisms, which mediate the

RA Inhibits Cardiac Hypertrophy through MAP Kinase Pathways
inhibitory effects of RA on cardiac hypertrophy. This is the first
report to demonstrate that hypertrophic stimuli-induced activation of MAP kinases is negatively regulated by RA, and that
the up-regulated expression of MKP-1 has an important role in
mediating the MAP kinase inhibition and antihypertrophic
effect of RA, in cyclic stretch- or Ang II-stimulated neonatal
cardiomyocytes. Further studies will be required to determine
whether this mechanism is operable in in vivo models of cardiac hypertrophy.
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